Predicted protein targets (top 4)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ENPP1 | P22413 | 17/20 | 0.85 |
| ▸ | FPR2 | P25090 | 1/20 | 0.52 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.51 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.51 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL20687574 | 0.92 | ENPP1 (1.00) | ENPP1 | |
| SCHEMBL20687504 | 0.91 | ENPP1 (0.72) | ENPP1SMN1; SMN2TDP1 | |
| SCHEMBL20679609 | 0.86 | ENPP1 (0.86) | ENPP1FPR2SMN1; SMN2TDP1 | |
| SCHEMBL20687583 | 0.85 | ENPP1 (0.86) | ENPP1FPR2 | |
| SCHEMBL20679602 | 0.83 | ENPP1 (0.67) | ENPP1FPR2 | |
| SCHEMBL30675621 | 0.81 | ENPP1 (0.86) | ENPP1FPR2 | |
| SCHEMBL20679561 | 0.81 | ENPP1 (0.86) | ENPP1FPR2 | |
| SCHEMBL20679556 | 0.80 | ENPP1 (0.87) | ENPP1FPR2 | |
| SCHEMBL30675552 | 0.80 | ENPP1 (0.87) | ENPP1FPR2 | |
| SCHEMBL30675602 | 0.78 | ENPP1 (0.87) | ENPP1FPR2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 12 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3658138-B1 | SUBSTITUTED-3H-IMIDAZO(4,5-C)PYRIDINE AND 1H-PYRROLO(2,3-C)PYRIDINE SERIES OF NOVEL ECTONUCLEOTIDE PYROPHSPHATASE/PHOSPHODIESTRASE-1 (ENPP1) AND STIMULATOR FOR INTERFERON GENES (STING) MODULATOR AS CANCER IMMUNOTHERAPEUTICS | STINGRAY THERAPEUTICS INC (US) | 2023-04-19 | — | — | EP | disclosed |
| US-11142524-B2 | Substituted-3H-imidazo[4,5-c]pyridine and 1H-pyrrolo[2,3-c]pyridine series of novel Ectonucleotide Pyrophosphatase/Phosphodiesterase-1 (ENPP1) and stimulator for interferon genes (STING) modulators as cancer immunotherapeutics | Stingray Therapeutics, Inc. (US) | 2021-10-12 | — | — | US | disclosed |
| US-11142524-B2 | Substituted-3H-imidazo[4,5-c]pyridine and 1H-pyrrolo[2,3-c]pyridine series of novel Ectonucleotide Pyrophosphatase/Phosphodiesterase-1 (ENPP1) and stimulator for interferon genes (STING) modulators as cancer immunotherapeutics | Stingray Therapeutics, Inc. (US) | 2021-10-12 | — | — | US | disclosed |
| EP-3829561-A1 | SUBSTITUTED-3H-IMIDAZO[4,5-C]PYRIDINE AND 1H PYRROLO[2,3-C]PYRIDINE SERIES OF NOVEL ECTONUCLEOTIDE PYROPHOSPHATASE/PHOSPHODIESTERASE-1 (ENPP1) AND STIMULATOR FOR INTERFERON GENES (STING) MODULATORS AS CANCER IMMUNOTHERAPEUTICS | Stingray Therapeutics, Inc. (US) | 2021-06-09 | — | — | EP | disclosed |
| US-10689376-B2 | Substituted-3H-imidazo [4,5-c] pyridine and 1H-pyrrolo[2,3-c]pyridine series of novel ectonucleotide pyrophosphatase/phosphodiesterase-1 (ENPP1) and stimulator for interferon genes (STING) modulators as cancer immunotherapeutics | Stingray Therapeutics, Inc. (US) | 2020-06-23 | — | — | US | disclosed |
| US-10689376-B2 | Substituted-3H-imidazo [4,5-c] pyridine and 1H-pyrrolo[2,3-c]pyridine series of novel ectonucleotide pyrophosphatase/phosphodiesterase-1 (ENPP1) and stimulator for interferon genes (STING) modulators as cancer immunotherapeutics | Stingray Therapeutics, Inc. (US) | 2020-06-23 | — | — | US | disclosed |
| US-20200039979-A1 | Substituted-3H-imidazo[4,5-c]pyridine and 1H-pyrrolo[2,3-c]pyridine series of novel Ectonucleotide Pyrophosphatase/Phosphodiesterase-1 (ENPP1) and Stimulator for Interferon Genes (STING) modulators as cancer immunotherapeutics | Stingray Therapeutics, Inc. | 2020-02-06 | — | — | US | disclosed |
| US-20200039979-A1 | Substituted-3H-imidazo[4,5-c]pyridine and 1H-pyrrolo[2,3-c]pyridine series of novel Ectonucleotide Pyrophosphatase/Phosphodiesterase-1 (ENPP1) and Stimulator for Interferon Genes (STING) modulators as cancer immunotherapeutics | Stingray Therapeutics, Inc. | 2020-02-06 | — | — | US | disclosed |
| WO-2020028724-A1 | SUBSTITUTED-3H-IMIDAZO[4,5-C]PYRIDINE AND 1H-PYRROLO[2,3-C]PYRIDINE SERIES OF NOVEL ECTONUCLEOTIDE PYROPHOSPHATASE/PHOSPHODIESTERASE-1 (ENPP1) AND STIMULATOR FOR INTERFERON GENES (STING) MODULATORS AS CANCER IMMUNOTHERAPEUTICS | Stingray Therapeutics, Inc. (US) | 2020-02-06 | — | — | WO | disclosed |
| WO-2020028724-A1 | SUBSTITUTED-3H-IMIDAZO[4,5-C]PYRIDINE AND 1H-PYRROLO[2,3-C]PYRIDINE SERIES OF NOVEL ECTONUCLEOTIDE PYROPHOSPHATASE/PHOSPHODIESTERASE-1 (ENPP1) AND STIMULATOR FOR INTERFERON GENES (STING) MODULATORS AS CANCER IMMUNOTHERAPEUTICS | Stingray Therapeutics, Inc. (US) | 2020-02-06 | — | — | WO | disclosed |
| US-20190031655-A1 | Substituted-3H-imidazo[4,5-c]pyridine and 1H-pyrrolo[2,3-c]pyridine series of novel Ectonucleotide Pyrophosphatase/Phosphodiesterase-1 (ENPP1) and Stimulator for Interferon Genes (STING) modulators as cancer immunotherapeutics | Stingray Therapeutics, Inc. | 2019-01-31 | — | — | US | disclosed |
| US-20190031655-A1 | Substituted-3H-imidazo[4,5-c]pyridine and 1H-pyrrolo[2,3-c]pyridine series of novel Ectonucleotide Pyrophosphatase/Phosphodiesterase-1 (ENPP1) and Stimulator for Interferon Genes (STING) modulators as cancer immunotherapeutics | Stingray Therapeutics, Inc. | 2019-01-31 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20200039979-A1 | Substituted-3H-imidazo[4,5-c]pyridine and 1H-pyrrolo[2,3-c]pyridine series of novel Ectonucleotide Pyrophosphatase/Phosphodiesterase-1 (ENPP1) and Stimulator for Interferon Genes (STING) modulators as cancer immunotherapeutics | STING1, ENPP1, CGAS | ENPP1 2/4885FPR2 2501/4885SMN1; SMN2 3292/4885 |
| US-20190031655-A1 | Substituted-3H-imidazo[4,5-c]pyridine and 1H-pyrrolo[2,3-c]pyridine series of novel Ectonucleotide Pyrophosphatase/Phosphodiesterase-1 (ENPP1) and Stimulator for Interferon Genes (STING) modulators as cancer immunotherapeutics | STING1, ENPP1, CGAS | ENPP1 2/4885FPR2 2501/4885SMN1; SMN2 3292/4885 |
| US-11142524-B2 | Substituted-3H-imidazo[4,5-c]pyridine and 1H-pyrrolo[2,3-c]pyridine series of novel Ectonucleotide Pyrophosphatase/Phosphodiesterase-1 (ENPP1) and stimulator for interferon genes (STING) modulators as cancer immunotherapeutics | STING1, ENPP1, CGAS | ENPP1 2/4885FPR2 2501/4885SMN1; SMN2 3292/4885 |
| US-10689376-B2 | Substituted-3H-imidazo [4,5-c] pyridine and 1H-pyrrolo[2,3-c]pyridine series of novel ectonucleotide pyrophosphatase/phosphodiesterase-1 (ENPP1) and stimulator for interferon genes (STING) modulators as cancer immunotherapeutics | STING1, ENPP1, CGAS | ENPP1 2/4885FPR2 2501/4885SMN1; SMN2 3292/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.